Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $257,550.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,151 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $50.00, for a total transaction of $257,550.00. Following the sale, the director now owns 300,695 shares in the company, valued at $15,034,750. This represents a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pro-Dex Stock Up 1.8 %

PDEX stock opened at $49.78 on Wednesday. Pro-Dex, Inc. has a 52-week low of $16.84 and a 52-week high of $59.60. The company’s 50 day simple moving average is $39.75 and its 200-day simple moving average is $38.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The firm has a market capitalization of $162.33 million, a P/E ratio of 24.77 and a beta of 0.68.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, equities research analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ritholtz Wealth Management purchased a new position in Pro-Dex during the fourth quarter valued at approximately $572,000. FMR LLC grew its position in Pro-Dex by 34.9% during the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares in the last quarter. Geode Capital Management LLC grew its position in Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after purchasing an additional 2,296 shares in the last quarter. JPMorgan Chase & Co. grew its position in Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after purchasing an additional 529 shares in the last quarter. Finally, 683 Capital Management LLC purchased a new position in Pro-Dex during the fourth quarter valued at approximately $739,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Pro-Dex from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.